Recent status of HIV-1 gene expression inhibitors

Antiviral Research

Volumn 71, Issue 2-3 SPEC. ISS., 2006, Pages 301-306

  Baba, Masanori ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Chemotherapy; HIV 1; NF B; Tat; Transcription

Indexed keywords

12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; 5,6 DICHLOROBENZIMIDAZOLE RIBOSIDE; ACETYLCYSTEINE; ALPHA N ACETYLNONA DEXTRO ARGININE AMIDE; ALPHA TOCOPHEROL; AMINOGLYCOSIDE DERIVATIVE; ANTHRACYCLINE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIOXIDANT; BENZIMIDAZOLE DERIVATIVE; CEPHARANTHINE; CYCLIN DEPENDENT KINASE 9; DOPAMINE DERIVATIVE; FLAVOPIRIDOL; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDIRUBIN 3' MONOXIME; K 37; LEPTOMYCIN B; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; N (6 AMINOHEXYL)GLYCYL N (3 GUANIDINOPROPYL)GLYCYL N (3 GUANIDINOPROPYL)GLYCYL N BENZYLGLYCYL N (3 GUANIDINOPROPYL)GLYCYL DEXTRO LYSYL DEXTRO LYSYL DEXTRO ARGINYL DEXTRO PROLINAMIDE; N ARACHIDONYLDOPAMINE; NEOMYCIN; PKF 050 638; PROTEIN KINASE C INHIBITOR; QUINOLONE DERIVATIVE; ROSCOVITINE; RW 67657; STAUROSPORINE; TR 87; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; WP 631;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; BREAST CANCER; CELL CULTURE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); DRUG TARGETING; GENE EXPRESSION; GENE INDUCTION; GENETIC TRANSCRIPTION; HOST CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG NON SMALL CELL CANCER; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN RNA BINDING; SHORT SURVEY; UNSPECIFIED SIDE EFFECT; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; GENE EXPRESSION REGULATION, VIRAL; GENE PRODUCTS, TAT; HIV INFECTIONS; HIV-1; HUMANS; NF-KAPPA B; PROTEIN KINASE INHIBITORS; TRANSCRIPTION, GENETIC;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33747140372     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2006.01.002     Document Type: Short Survey

References (49)

1. Agbottah E., de La Fuente C., Nekhai S., Barnett A., Gianella-Borradori A., Pumfery A., and Kashanchi F. Antiviral activity of CYC202 in HIV-1-infected cells. J. Biol. Chem. 280 (2005) 3029-3042
2. Baba M., Okamoto M., Kawamura M., Makino M., Higashida T., Takashi T., Kimura Y., Ikeuchi T., Tetsuka T., and Okamoto T. Inhibition of human immunodeficiency virus type 1 replication and cytokine production by fluoroquinoline derivatives. Mol. Pharmacol. 53 (1998) 1097-1103
3. Baba M. Inhibitors of HIV-1 gene expression and transcription. Curr. Top. Med. Chem. 4 (2004) 871-883
4. Cabrera C., Gutierrez A., Blanco J., Barretina J., Litovchick A., Lapidot A., Evdokimov A.G., Clotet B., and Este J.A. Anti-human immunodeficiency virus activity of novel aminoglycoside-arginine conjugates at early stages of infection. AIDS Res. Hum. Retroviruses 16 (2000) 627-634
5. Daelemans D., Schols D., Witvrouw M., Pannecouque C., Hatse S., van Dooren S., Hamy F., Klimkait T., De Clercq E., and VanDamme A.M. A second target for the peptoid Tat/transactivation response element inhibitor CGP64222: inhibition of human immunodeficiency virus replication by blocking CXC-chemokine receptor 4-mediated virus entry. Mol. Pharmacol. 57 (2000) 116-124
6. Daelemans D., Afonina E., Nilsson J., Werner G., Kjems J., De Clercq E., Pavlakis G.N., and Vandamme A.M. A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 14440-14445
7. Doranz B.J., Grovit-Ferbas K., Sharron M.P., Mao S.H., Goetz M.B., Daar E.S., Doms R.W., and O'Brien W.A. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J. Exp. Med. 186 (1997) 1395-1400
8. Ghosh S., May M.J., and Kopp E.B. NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 16 (1998) 225-260
9. Ghosh S., and Karin M. Missing pieces in the NF-κB puzzle. Cell 109 (2002) S81-S96
10. Hamy F., Felder E.R., Heizmann G., Lazdins J., Aboul-ela F., Varani G., Karn J., and Klimkait T. An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 3548-3553
11. Heredia A., Davis C., Bamba D., Le N., Gwarzo M.Y., Sadowska M., Gallo R.C., and Redfield R.R. Indirubin-3′-monoxime, a derivative of a Chinese antileukemia medicine, inhibits P-TEFb function and HIV-1 replication. AIDS 19 (2005) 2087-2095
12. Hirsch M.S., Brun-Vezinet F., Clotet B., Conway B., Kuritzkes D.R., D'Aquila R.T., Demeter L.M., Hammer S.M., Johnson V.A., Loveday C., Mellors J.W., Jacobsen D.M., and Richman D.D. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin. Infect. Dis. 37 (2003) 113-128
13. Hwang S., Tamilarasu N., Kibler K., Cao H., Ali A., Ping Y.H., Jeang K.T., and Rana T.M. Discovery of a small molecule Tat-trans-activation-responsive RNA antagonist that potently inhibits human immunodeficiency virus-1 replication. J. Biol. Chem. 278 (2003) 39092-39103
14. Israel N., Gougerot-Pocidalo M.A., Aillet F., and Virelizier J.L. Redox status of cells influences constitutive or induced NF-kappa B translocation and HIV long terminal repeat activity in human T and monocytic cell lines. J. Immunol. 149 (1992) 3386-3393
15. Johnson V.A., Brun-Vézinet F., Clotet B., Conway B., Kuritzkes D.R., Pillay D., Schapiro J., Telenti A., and Richman D.D. Update of the drug resistance mutations in HIV-1. Top. HIV Med. 13 (2005) 51-57
16. Karn J. Tackling Tat. J. Mol. Biol. 293 (1999) 235-254
17. Kutsch O., Levy D.N., Bates P.J., Decker J., Kosloff B.R., Shaw G.M., Priebe W., and Benveniste E.N. Bis-anthracycline antibiotics inhibit human immunodeficiency virus type 1 transcription. Antimicrob. Agents Chemother. 48 (2004) 1652-1663
18. Kudo N., Matsumori N., Taoka H., Fujiwara D., Schreiner E.P., Wolff B., Yoshida M., and Horinouchi S. Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 9112-9117
19. Laurence J., Sikder S.K., Jhaveri S., and Salmon J.E. Phorbol ester-mediated induction of HIV-1 from a chronically infected promonocyte clone: blockade by protein kinase inhibitors and relationship to tat-directed trans-activation. Biophys. Biochem. Res. Commun. 166 (1990) 349-357
20. Litovchick A., Evdokimov A.G., and Lapidot A. Aminoglycoside-arginine conjugates that bind TAR RNA: synthesis, characterization, and antiviral activity. Biochemistry 39 (2000) 2838-2852
21. Mancebo H.S., Lee G., Flygare J., Tomassini J., Luu P., Zhu Y., Peng J., Blau C., Hazuda D., Price D., and Flores O. P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. Gene Dev. 11 (1997) 2633-2644
22. Murata T., Shimada M., Sakakibara S., Yoshino T., Kadono H., Masuda T., Shimazaki M., Shintani T., Fuchikami K., Sakai K., Inbe H., Takeshita K., Niki T., Umeda M., Bacon K.B., Ziegelbauer K.B., and Lowinger T.B. Discovery of novel and selective IKK-beta serine-threonine protein kinase inhibitors. Part 1. Bioorg. Med. Chem. Lett. 13 (2003) 913-918
23. Muthumani K., Wadsworth S.A., Dayes N.S., Hwang D.S., Choo A.Y., Abeysinghe H.R., Siekierka J.J., and Weiner D.B. Suppression of HIV-1 viral replication and cellular pathogenesis by a novel p38/JNK kinase inhibitor. AIDS 18 (2004) 739-748
24. Nekhai S., Shukla R.R., and Kumar A. A human primary T-lymphocyte-derived human immunodeficiency virus type 1 Tat-associated kinase phosphorylates the C-terminal domain of RNA polymerase II and induces CAK activity. J. Virol. 71 (1997) 7436-7441
25. O'Brien W.A., Sumner-Smith M., Mao S.H., Sadeghi S., Zhao J.Q., and Chen I.S. Anti-human immunodeficiency virus type 1 activity of an oligocationic compound mediated via gp120 V3 interactions. J. Virol. 70 (1996) 2825-2831
26. Okamoto M., Ono M., and Baba M. Potent inhibition of HIV type 1 replication by an antiinflammatory alkaloid, cepharanthine, in chronically infected monocytic cells. AIDS Res. Hum. Retroviruses 14 (1998) 1239-1245
27. Okamoto H., Cujec T.P., Okamoto M., Peterlin B.M., Baba M., and Okamoto T. Inhibition of the RNA-dependent transactivation and replication of human immunodeficiency virus type 1 by a fluoroquinoline derivative K-37. Virology 272 (2000) 402-408
28. Pande V., and Ramos M.J. Nuclear factor kappa B: a potential target for anti-HIV chemotherapy. Curr. Med. Chem. 10 (2003) 1603-1615
29. Parolin C., Gatto B., Del Vecchio C., Pecere T., Tramontano E., Cecchetti V., Fravolini A., Masiero S., Palumbo M., and Palù G. New anti-human immunodeficiency virus type 1 6-aminoquinolones: mechanism of action. Antimicrob. Agents Chemother. 47 (2003) 889-896
30. Peng J., Zhu Y., Milton J.T., and Price D.H. Identification of multiple cyclin subunits of human P-TEFb. Gene Dev. 12 (1998) 755-762
31. Richter S., Parolin C., Gatto B., Del Vecchio C., Brocca-Cofano E., Fravolini A., Palù G., and Palumbo M. Inhibition of human immunodeficiency virus type 1 Tat-trans-activation-responsive region interaction by an antiviral quinolone derivative. Antimicrob. Agents Chemother. 48 (2004) 1895-1899
32. Pollard V.W., and Malim M.H. The HIV Rev protein. Annu. Rev. Microbiol. 52 (1998) 491-532
33. Price D.H. P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II. Mol. Cell. Biol. 20 (2000) 2629-2634
34. Qatsha K.A., Rudolph C., Marme D., Schachtele C., and May W.S. Gö 6976, a selective inhibitor of protein kinase C, is a potent antagonist of human immunodeficiency virus 1 induction from latent/low-level-producing reservoir cells in vitro. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 4674-4678
35. Roederer M., Staal F.J., Raju P.A., Ela S.W., Herzenberg L.A., and Herzenberg L.A. Cytokine-stimulated human immunodeficiency virus replication is inhibited by N-acetyl-l-cysteine. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 4884-4888
36. Sancho R., Macho A., de La Vega L., Calzado M.A., Fiebich B.L., Appendino G., and Munoz E. Immunosuppressive activity of endovanilloids: N-arachidonoyldopamine inhibits activation of the NF-κB, NFAT, and activator protein 1 signaling pathways. J. Immunol. 172 (2004) 2341-2351
37. Sancho R., de la Vega L., Macho A., Appendino G., Di Marzo V., and Munoz E. Mechanisms of HIV-1 inhibition by the lipid mediator N-arachidonoyldopamine. J. Immunol. 175 (2005) 3990-3999
38. Stadler W.M., Vogelzang N.J., Amato R., Sosman J., Taber D., Liebowitz D., and Vokes E.E. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. J. Clin. Oncol. 18 (2000) 371-375
39. Struble K., Murray J., Cheng B., Gegeny T., Miller V., and Gulick R. Antiretro-viral therapies for treatment-experienced patients: current status and research challenges. AIDS 19 (2005) 747-756
40. Schwartz G.K., Ilson D., Saltz L., O'Reilly E., Tong W., Maslak P., Werner J., Perkins P., Stoltz M., and Kelsen D. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J. Clin. Oncol. 19 (2001) 1985-1992
41. Viatour P., Merville M.P., Bours V., and Chariot A. Phosphorylation of NF-κB and IκB proteins: implications in cancer and inflammation. Trends Biochem. Sci. 30 (2005) 43-52
42. Victoriano A.F., Asamitsu K., Hibi Y., Imai K., Barzaga N.G., and Okamoto T. Inhibition of human immunodeficiency virus type 1 replication in latently infected cells by a novel IκB kinase inhibitor. Antimicrob. Agents Chemother. 50 (2006) 547-555
43. Wang D., de la Fuente C., Deng L., Wang L., Zilberman I., Eadie C., Healey M., Stein D., Denny T., Harrison L.E., Meijer L., and Kashanchi F. Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors. J. Virol. 75 (2001) 7266-7279
44. Wei P., Garber M.E., Fang S.M., Fischer W.H., and Jones K.A. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 92 (1998) 451-462
45. Wolff B., Sanglier J.J., and Wang Y. Leptomycin B is an inhibitor of nuclear export: inhibition of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-1) Rev protein and Rev-dependent mRNA. Chem. Biol. 4 (1997) 139-147
46. Yeni P.G., Hammer S.M., Carpenter C.C., Cooper D.A., Fischl M.A., Gatell J.M., Gazzard B.G., Hirsch M.S., Jacobsen D.M., Katzenstein D.A., Montaner J.S., Richman D.D., Saag M.S., Schechter M., Schooley R.T., Thompson M.A., Vella S., and Volberding P.A. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 288 (2002) 222-235
47. Zapp M.L., Stern S., and Green M.R. Small molecules that selectively block RNA binding of HIV-1 Rev protein inhibit Rev function and viral production. Cell 74 (1993) 969-978
48. Zhai S., Senderowicz A.M., Sausville E.A., and Figg W.D. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development. Ann. Pharmacother. 36 (2002) 905-911
49. Zhang J., Tamilarasu N., Hwang S., Garber M.E., Huq I., Jones K.A., and Rana T.M. HIV-1 TAR RNA enhances the interaction between Tat and cyclin T1. J. Biol. Chem. 275 (2000) 34314-34319